Cargando…

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Detalles Bibliográficos
Autores principales:	Trotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher K., Cochrane, Tara, Badoux, Xavier, Carlson, Julia, Nkhoma, Gloria, Butcher, Belinda, Nikpour, Armin, Fulham, Michael, Johnston, Anna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946407/ https://www.ncbi.nlm.nih.gov/pubmed/36844180 http://dx.doi.org/10.1097/HS9.0000000000000836

Ejemplares similares

P1127: FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL
por: Verner, Emma, et al.
Publicado: (2023)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
por: Zinzani, P. L., et al.
Publicado: (2013)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
por: Yilmaz, Umut, et al.
Publicado: (2021)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
por: Yamshon, Samuel, et al.
Publicado: (2023)

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study
por: Zhang, Yan, et al.
Publicado: (2021)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance
por: Boyle, Stephen, et al.
Publicado: (2021)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
por: Butler, M., et al.
Publicado: (1997)

Familial Aggregation of Non-Hodgkin's Lymphoma (NHL). A Case Report
por: Loves, Sandra SCM, et al.
Publicado: (2006)

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
por: Doorduijn, J., et al.
Publicado: (2022)

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
por: Barraclough, Allison, et al.
Publicado: (2023)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
por: Zinzani, P. L., et al.
Publicado: (2022)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

Assessment of bone marrow infiltration in B-cell non-Hodgkin's lymphoma (NHL).
por: Dorey, E. L., et al.
Publicado: (1989)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Lenalidomide in Diffuse Large B-Cell Lymphoma
por: Thieblemont, Catherine, et al.
Publicado: (2012)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
por: Silvestre, Antonio Salar, et al.
Publicado: (2023)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Herbicide use in farming and other jobs in relation to non-Hodgkin’s lymphoma (NHL) risk
por: De Roos, Anneclaire J, et al.
Publicado: (2022)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Successful Treatment of Concomitant Pleural Mucosa-Associated Lymphoid Tissue Lymphoma and Monoclonal Gammopathy of Undetermined Significance with Lenalidomide, Rituximab, and Dexamethasone
por: Uemura, Yoshiki, et al.
Publicado: (2022)

Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times
por: Sica, Antonello, et al.
Publicado: (2019)

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
por: Nagle, Sarah J, et al.
Publicado: (2017)

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
por: Garau, Martina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qvnjia46sdpd3mlciftmcm58t8